Valorization of Lactobacilli and their Antimicrobial Peptides for Reproductive and Intimate Health Enhancement
The VALERIE project aims to purify and characterize antimicrobial compounds from vaginal lactobacilli to develop innovative treatments against antibiotic-resistant pathogens.
Projectdetails
Introduction
In an era marked by escalating concerns over antibiotic and antimycotic resistance as the next major global pandemic, the need to explore unconventional sources of antimicrobial agents has become increasingly urgent.
Background
In this context, lactobacilli, traditionally renowned for their probiotic and food applications, have recently emerged as a promising source of novel antimicrobial strategies. These lactic acid bacteria, abundant in various natural habitats including the human vagina and fermented foods, present a unique source for the discovery of novel antimicrobial compounds.
The compounds are valuable as such when purified and when combined with the producing lactobacilli, they are used as live biotherapeutic products or probiotics.
Project Overview
The VALERIE project starts from recent discoveries in the host laboratory that lactobacilli from the vagina can produce specialized antimicrobials, including novel bacteriocin-types. This discovery is particularly appealing since gynaecology and women’s health is an area in medicine which urgently needs new antimicrobials.
Objectives
VALERIE aims to bring these discoveries to a higher Technology Readiness Level (TRL4). Our objectives include:
- Purifying and characterizing these compounds.
- Assessing their antimicrobial efficacy against key pathogens, including fungi like Candida albicans and ESKAPE pathogens.
- Elucidating their mode of action.
Methodology
Hereto, we will assess the safety and efficacy of the purified compounds and producing lactobacilli in silico, in vitro, and in vivo. We will also initiate the development of a multispecies lactobacilli formulation for applications with the live producing micro-organisms.
Expected Outcomes
These experiments will result in a robust dataset that can attract industrial partners for future endeavors aimed at clinical applications. Through innovative approaches, we aspire to unveil and harness the untapped antimicrobial potential of lactobacilli, providing a ray of hope in our ongoing battle against antibiotic resistance.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-5-2025 |
Einddatum | 31-10-2026 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT ANTWERPENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bacteriocins from interbacterial warfare as antibiotic alternativeBACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered ProphagesPHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine. | ERC Starting... | € 1.500.000 | 2025 | Details |
PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential. | ERC Proof of... | € 150.000 | 2024 | Details |
Microbial Synthetic in vivo Cell Therapy SystemsThe MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways. | ERC Starting... | € 1.499.938 | 2023 | Details |
Postbiotic Restoration Of the Metabolome Of MomsPRO-MOM aims to develop a postbiotic supplement to restore maternal-neonatal microbiota and mitigate behavioral disturbances in offspring following antibiotic use during pregnancy and breastfeeding. | ERC Proof of... | € 150.000 | 2024 | Details |
Bacteriocins from interbacterial warfare as antibiotic alternative
BACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health.
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages
PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.
PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.
Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential.
Microbial Synthetic in vivo Cell Therapy Systems
The MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways.
Postbiotic Restoration Of the Metabolome Of Moms
PRO-MOM aims to develop a postbiotic supplement to restore maternal-neonatal microbiota and mitigate behavioral disturbances in offspring following antibiotic use during pregnancy and breastfeeding.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
FERTI-LILY Probiotic GelRosesta Medical ontwikkelt innovatieve probiotische behandelingen om het vaginale microbioom te stabiliseren en de conceptiekansen te verhogen, met focus op de Lactobacillus crispatus bacterie. | Mkb-innovati... | € 20.000 | 2020 | Details |
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistanceMaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials. | EIC Pathfinder | € 3.194.450 | 2024 | Details |
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitisGedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance. | EIC Accelerator | € 2.499.999 | 2024 | Details |
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTHiNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment. | EIC Pathfinder | € 3.194.343 | 2025 | Details |
FERTI-LILY Probiotic Gel
Rosesta Medical ontwikkelt innovatieve probiotische behandelingen om het vaginale microbioom te stabiliseren en de conceptiekansen te verhogen, met focus op de Lactobacillus crispatus bacterie.
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistance
MaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials.
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis
Gedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance.
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTH
iNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment.